{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:18:22Z","timestamp":1769559502788,"version":"3.49.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Internal Medicine Association of Limoges University Hospital"},{"name":"Limoges University Hospital Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:p>Bullous pemphigoid mainly affects older people with various comorbidities. The disease has a high mortality rate due to the disease itself and to the side effects of systemic treatments. The aim of this study was to identify blood and skin predictive factors for therapeutic response at diagnosis, so that patients can be offered the most appropriate treatment for their condition as quickly as possible. A prominent Th2 response was identified in patients whose disease was resistant to first-line treatment. It was possible to predict resistance to first-line treatment in BP through skin IL-4-, IL-13- and IL-5-expressing cells. In contrast, CD68 and skin IFN-\u03b3-expressing cells (Th1 profile) were associated with sensitivity to first-line treatment.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf430","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:40:39Z","timestamp":1762173639000},"page":"392-395","source":"Crossref","is-referenced-by-count":0,"title":["Specific serum and skin immunological profiles of patients with bullous pemphigoid requiring biologics"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-8742","authenticated-orcid":false,"given":"Salom\u00e9","family":"Fourmond","sequence":"first","affiliation":[{"name":"Department of Dermatology, Centre de R\u00e9f\u00e9rence Maladies Rares des Maladies Bulleuses Auto-immunes (MALIBUL), University Hospital , Limoges ,","place":["France"]},{"name":"INSERM U 1308 CAPTuR, Limoges University , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Dumonteil","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein","family":"Akil","sequence":"additional","affiliation":[{"name":"INSERM U 1308 CAPTuR, Limoges University , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelie","family":"Couraud","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centre de R\u00e9f\u00e9rence Maladies Rares des Maladies Bulleuses Auto-immunes (MALIBUL), University Hospital , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Audevard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centre de R\u00e9f\u00e9rence Maladies Rares des Maladies Bulleuses Auto-immunes (MALIBUL), University Hospital , Limoges ,","place":["France"]},{"name":"Department of Pathology, University Hospital , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Belle-Moudourou","sequence":"additional","affiliation":[{"name":"Department of Immunology, University Hospital , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Odile","family":"Jauberteau","sequence":"additional","affiliation":[{"name":"INSERM U 1308 CAPTuR, Limoges University , Limoges ,","place":["France"]},{"name":"Department of Immunology, University Hospital , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Bernard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centre de R\u00e9f\u00e9rence Maladies Rares des Maladies Bulleuses Auto-immunes (MALIBUL), University Hospital , Limoges ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026012706483007400_ljaf430-B1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2026012706483007400_ljaf430-B2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/bjd\/ljae219","article-title":"Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids","volume":"191","author":"Kridin","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026012706483007400_ljaf430-B3","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.3390\/jcm13164844","article-title":"Omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review","volume":"13","author":"Granados-Betancort","year":"2024","journal-title":"J Clin Med"},{"key":"2026012706483007400_ljaf430-B4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026012706483007400_ljaf430-B5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2\u2005K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026012706483007400_ljaf430-B6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2026012706483007400_ljaf430-B7","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/exd.13408","article-title":"Glucocorticoids: the mode of action in bullous pemphigoid","volume":"26","author":"Kubin","year":"2017","journal-title":"Exp Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf430\/65137326\/ljaf430.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/2\/392\/65137326\/ljaf430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/2\/392\/65137326\/ljaf430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:48:41Z","timestamp":1769514521000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/2\/392\/8313689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":7,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf430","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,4]]}}}